DCA Forms Task Force To Investigate Smilax And Biogenetic Operations

Shimla: In a startling revelation, pharmaceutical giants Smilax and Biogenetic find themselves embroiled in a controversy surrounding the alleged illicit sale of banned drugs across state borders. The companies, previously regarded as pillars of the pharmaceutical industry, now face intense scrutiny and accusations of regulatory violations.

The Drug Control Administration has formed a task force to delve into the operations of both companies. Led by seasoned investigators and drug control experts, this task force is tasked with uncovering any potential breaches of drug regulations and ensuring accountability within the pharmaceutical sector.

The allegations against Smilax and Biogenetic stem from reports of medicines being distributed in Punjab without the requisite information to law enforcement and regulatory authorities. Such actions not only contravene established protocols but also raise serious concerns regarding public health and safety.

Recent raids conducted by Punjab Police at the premises of both companies have yielded damning evidence, including the discovery of banned medicines and irregularities in documentation. These findings have prompted legal action against the companies, with show-cause notices issued and the prospect of further repercussions looming large.

Of particular concern is the potential nexus with the Narcotic Drugs and Psychotropic Substances (NDPS) Act, as authorities investigate claims of illegal drug sales beyond authorized jurisdictions. The implications of such violations extend far beyond mere regulatory oversight, posing significant challenges to law enforcement agencies and public health authorities alike.

Related Posts

  • Pharma
  • May 25, 2024
  • 64 views
NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) under…

  • Pharma
  • May 25, 2024
  • 75 views
Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Jaipur: To provide quality education in pharmacy institutes, the central government has prepared to end the duplicate system. Strict action will be taken against fake students and teachers in newly opened…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

A Doctor diagnoses Mood of Voters in Delhi

A Doctor diagnoses Mood of Voters in Delhi

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

NPPA Revises Ceiling Price Of Asthma Inhaler Drug Combination In Suo-Moto Correction

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Students Will Not Be Able To Take Admission In Pharmacy Institutes With Fake Documents, Strict Monitoring

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Tripura Police Seized Banned Cough Syrup Worth Rs 30 Lakh In Dhalai; One Arrested

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Ex-Pharmacy Council Registrar Gave Certificates To Ineligible Candidates?

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research

Experts Call For Ethical Standards, Patient Advocacy In Clinical Research